Cardiotoxicity associated with doxorubicin
Intended for healthcare professionals
Clinical Previous     Next

Cardiotoxicity associated with doxorubicin

Jane Mallinson Ward Sister, Regional Oncology Unit, Royal Liverpool Children’s Hospital, Alder Hey NHS Trust, Liverpool

Anthracyclines, of which doxorubicin is the most common, have been effective chemotherapy agents for over 20 years; however they are plagued by problems of cardiotoxicity (O’Marcaigh and Betcher 1997). Irreversible myocardial toxicity, manifested in its most severe form by life-threatening congestive heart failure, may occur either during therapy or months to years after stopping treatment. The frequency of cardiomyopathy can be reduced by modifying the schedule of administration, patient selection, careful cardiac monitoring, less toxic doxorubicin analogues or pharmacological intervention. Nurses should be aware of this severe side effect of a highly effective and widely used chemotherapeutic drug, how to spot cardiotoxicity in cancer patients and how it can be treated.

Cancer Nursing Practice. 2, 9, 30-34. doi: 10.7748/cnp2003.11.2.9.30.c98

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more